GlassScriptPhysician profile
Evangeline Ojales
NPI 1023405081
$7,351.88
in general payments reported to CMS, 2019-2025
27 companies · $2,358 in 2025
The $2,358 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $359 · 2023: $1,406 · 2024: $3,079 · 2025: $2,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,842.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,076.48 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $916.28 | 2022-2024 | Xarelto |
| Gilead Sciences, INC. | $730.01 | 2023-2025 | Vemlidy, Veklury, Yeztugo |
| Astellas Pharma US INC | $595.28 | 2023-2025 | Veozah, Cresemba, Lexiscan |
| Astrazeneca Pharmaceuticals LP | $575.00 | 2023-2025 | Calquence, Evusheld |
| Madrigal Pharmaceuticals | $362.97 | 2024-2025 | Rezdiffra |
| Sobi, INC | $253.74 | 2024-2025 | |
| Sk Life Science, INC. | $241.89 | 2022-2023 | Xcopri |
| Pfizer INC. | $231.36 | 2024-2025 | |
| Blueprint Medicines Corporation | $226.14 | 2024 | Ayvakit |
| Grifols USA, LLC | $174.94 | 2025 | Hyperrab |
| Janssen Scientific Affairs, LLC | $162.12 | 2024 | |
| Neurelis, INC. | $149.80 | 2021 | |
| Aurinia Pharma U.S., INC. | $142.28 | 2024 | Lupkynis |
| Servier Pharmaceuticals LLC | $140.88 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $134.68 | 2023 | |
| Rigel Pharmaceuticals, INC. | $131.29 | 2025 | Rezlidhia |
| Springworks Therapeutics, INC. | $126.78 | 2024 | Ogsiveo |
| Jazz Pharmaceuticals INC. | $125.86 | 2025 | |
| Genzyme Corporation | $124.89 | 2025 | |
| Daiichi Sankyo INC. | $123.79 | 2025 | Vanflyta |
| Genmab U.S., INC. | $121.73 | 2024 | Epkinly |
| Janssen Biotech, INC. | $121.13 | 2025 | Rybrevant, Carvykti |
| Sanofi-Aventis U.S. LLC | $120.90 | 2025 | |
| Glaxosmithkline, LLC. | $115.47 | 2024 | Jemperli |
| Merck Sharp & Dohme LLC | $111.74 | 2025 | Lynparza |
| Smith+Nephew, INC. | $14.45 | 2025 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evangeline Ojales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.